Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
Regencell Bioscience Holdings Limited recently participated in a video interview with SNN Network, discussing their focus on Traditional Chinese Medicine (TCM) for treating neurocognitive disorders like ADHD and ASD, as well as infectious diseases. The company aims to launch three standardized TCM formulas for varying severities of ADHD and ASD patients, starting in Hong Kong. Additionally, they plan to provide COVID-related treatments in ASEAN countries, India, Japan, Australia, and New Zealand. The interview is available on their official website.
- Completion of first research study on TCM treatment for ADHD and ASD.
- Plans to launch three standardized TCM formulas targeting ADHD and ASD.
- Formation of a joint venture for COVID-related treatments across multiple countries.
- None.
LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, according to the company's website (see here: www.regencellbioscience.com).
Click the following link to watch the Video Interview:
Regencell on Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results
You can follow SNN Network on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE
Please review important disclosures on our website at: https://snn.network/terms-of-use
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is an early-stage bioscience company that commenced operations in Hong Kong is 2014. Regencell focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune system such as COVID. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently to other markets as it deems appropriate. The Company formed a joint venture to offer COVID related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
For more information about Regencell, please visit: www.regencellbioscience.com
About SNN Network
SNN Network is an investor portal covering the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to our YouTube Channel to be notified when new CEO video interviews, Wall Street Views with investing experts, and Planet MicroCap Podcast episodes are available.
Subscribe NOW to SNN Network: http://bit.ly/1Q5Yfym
SNN Network
SOURCE: Stock News Now
View source version on accesswire.com:
https://www.accesswire.com/690804/Regencell-Describes-Their-Traditional-Chinese-Medicine-TCM-Treatments-and-Recent-Efficacy-Trial-Results-in-New-Video-Interview-on-SNN-Network
FAQ
What is Regencell Bioscience Holdings Limited's stock symbol?
What is the focus of Regencell's research and development?
What conditions are targeted by Regencell's TCM treatments?
Where did Regencell complete its first research study?
What are Regencell's plans for COVID-related treatments?
